Vivos Therapeutics to Report Financial Results and Call Details
Vivos Therapeutics to Announce Second Quarter Financials
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a trailblazer in medical device technology, is set to release its financial results for the second quarter of 2025. The announcement marks a significant point for the company, which specializes in developing effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe cases in children.
Details of the Financial Release
The much-anticipated financial results will be released after market closure, allowing stakeholders to digest the information thoroughly. Following the results announcement, Vivos Therapeutics will host a conference call at 5:00 PM Eastern Time. This call provides an invaluable opportunity for investors to gain insights into the company's recent achievements and strategic plans moving forward.
Participating in the Conference Call
Investors and interested parties can access the conference call by dialing (800) 717-1738, with international callers using (646) 307-1865. A replay of the call will be made available shortly after its conclusion, accessible at (844) 512-2921 for domestic callers and (412) 317-6671 for international participants. The replay will remain available until early September, providing ample time for review.
Accessing the Live Webcast
For those who prefer a digital format, Vivos Therapeutics encourages everyone to view the live webcast on their official website. The recording will also be archived for 30 days for those unable to attend the live session, ensuring accessibility for all interested stakeholders.
About Vivos Therapeutics
Vivos Therapeutics, Inc. is dedicated to improving the lives of individuals suffering from sleep disorders linked to dentofacial abnormalities. The company is committed to addressing the needs of OSA and snoring patients through innovative devices such as their Complete Airway Repositioning and Expansion (CARE) systems. These products have gained FDA clearance for treating OSA in patients aged 6 to 17, making Vivos the first provider to secure such approval for children.
The Impact of OSA Worldwide
With over 1 billion individuals affected by OSA globally, the condition remains alarmingly underdiagnosed, with approximately 90% of those affected unaware of their situation. This serious condition is intertwined with several health complications. Traditional treatments like CPAP often overlook the root causes, highlighting the importance of Vivos' approach.
Vivos' Unique Approach
Founded in 2016, Vivos Therapeutics is carving a niche in the medical field through education, technology, and strategic collaborations. Their methodology, known as The Vivos Method, emphasizes a nonsurgical, noninvasive, and nonpharmaceutical approach to treatment, providing hope to those who seek to breathe freely and lead healthier lives.
Continuing Innovations in Sleep Health
Vivos is continuously working to innovate within the realm of sleep health. By acquiring sleep healthcare practices and developing cutting-edge technology, the company is positioned to further revolutionize how sleep disorders, particularly OSA, are diagnosed and treated.
Frequently Asked Questions
What is Vivos Therapeutics focusing on in their upcoming release?
Vivos Therapeutics will announce its financial results and discuss recent milestones and future developments.
How can one participate in the conference call?
Interested parties can join the conference call by dialing the specified phone numbers shared by Vivos Therapeutics.
What products does Vivos specialize in?
Vivos focuses on proprietary treatments for sleep-related breathing disorders, particularly for individuals with obstructive sleep apnea.
Why is the upcoming financial report significant?
The financial report presents an opportunity to assess Vivos' performance and strategic developments in the last quarter.
How does Vivos support OSA patients?
Through innovative technologies and The Vivos Method, the company addresses the needs of OSA and snoring patients effectively and compassionately.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.